logo-loader
viewReNeuron Group PLC

ReNeuron's Michael Hunt explains new emphasis on its retinal and exosome technology programmes

ReNeuron Group PLC's (LON:RENE) Michael Hunt speaks to Proactive London's Andrew Scott soon after receiving regulatory approvals in the US and UK to expand its phase IIa stem cell studies in people with the degenerative eye disease retinitis pigmentosa.

Hunt also discusses why they'll now be focusing its in-house activities on the retinal disease programme and developing its exosome-based technology.

Quick facts: ReNeuron Group PLC

Price: 115 GBX

LSE:RENE
Market: LSE
Market Cap: £36.63 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ReNeuron's Michael Hunt says key focus now is to build dataset for retinal...

ReNeuron Group PLC's (LON:RENE) Michael Hunt speaks to Proactive London's Andrew Scott on the back of its results for the year to the end of March 2020. He says one of the main highlights has been the continuation of the retinal disease clinical study in the US. A recent update showed the...

3 weeks, 4 days ago

2 min read